Highbridge Capital Management’s United Therapeutics UTHR Stock Holding History

Highbridge Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-91,698	Closed	-$10.8M	–	1608
2016 Q3	$10.8M	Buy	91,698 +40,305	+78%	+$4.84M	0.17%	139
2016 Q2	$5.44M	Buy	51,393 +14,096	+38%	+$1.57M	0.09%	248
2016 Q1	$4.16M	Sell	37,297 -27,882	-43%	-$3.53M	0.07%	326
2015 Q4	$10.2M	Buy	65,179 +62,978	+2,861%	+$9.17M	0.16%	167
2015 Q3	$288K	Sell	2,201 -10,351	-82%	-$1.66M	﹤0.01%	1250
2015 Q2	$2.18M	Buy	12,552 +55	+0.4%	+$9.89K	0.03%	502
2015 Q1	$2.15M	Buy	+12,497	New	+$1.91M	0.03%	517
2014 Q3	–	Sell	-29,229	Closed	-$2.59M	–	1375
2014 Q2	$2.59M	Buy	+29,229	New	+$2.81M	0.03%	375
2013 Q3	–	Sell	-11,182	Closed	-$736K	–	1532
2013 Q2	$736K	Buy	+11,182	New	+$720K	0.01%	761

Other funds holding UTHR

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JIM

Jupiter Investment Management London, United Kingdom $6.26B AUM 13.19% 1-Year Est. Return

Highbridge Capital Management's UTHR Position: Q4 2016 in Review

Highbridge Capital Management sold out of United Therapeutics (UTHR) in Q4 2016, closing a stake of 91,698 shares — an estimated $10.8M sold.

Highbridge Capital Management first reported a position in UTHR in Q2 2013 and held it in 9 quarters. The position peaked at $10.8M in Q3 2016. 406 funds tracked by Wall St. Rank hold UTHR as of Q4 2016.

Highbridge Capital Management reported no remaining United Therapeutics position as of Q4 2016 after selling out during the quarter.
Highbridge Capital Management sold 91,698 United Therapeutics shares in Q4 2016, an estimated $10.8M.
Highbridge Capital Management first reported a position in United Therapeutics in Q2 2013 and held it in 9 quarters.
Highbridge Capital Management's United Therapeutics position peaked at $10.8M in Q3 2016.
406 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2016.

Based on Highbridge Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.